Kiromic BioPharma, Inc. (NASDAQ:KRBP) Expected to Post Earnings of -$0.29 Per Share

Wall Street brokerages expect Kiromic BioPharma, Inc. (NASDAQ:KRBPGet Rating) to announce earnings per share of ($0.29) for the current quarter, according to Zacks. Zero analysts have made estimates for Kiromic BioPharma’s earnings. Kiromic BioPharma reported earnings per share of ($0.53) during the same quarter last year, which would suggest a positive year over year growth rate of 45.3%. The business is expected to issue its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Kiromic BioPharma will report full-year earnings of ($1.45) per share for the current financial year. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Kiromic BioPharma.

Kiromic BioPharma (NASDAQ:KRBPGet Rating) last posted its quarterly earnings results on Friday, March 11th. The company reported ($0.40) earnings per share for the quarter.

Shares of KRBP opened at $0.51 on Friday. Kiromic BioPharma has a 52 week low of $0.49 and a 52 week high of $11.00. The company has a market capitalization of $7.98 million, a price-to-earnings ratio of -0.60 and a beta of 0.61. The stock’s 50-day moving average price is $0.76 and its 200-day moving average price is $1.41.

Several institutional investors and hedge funds have recently modified their holdings of the company. 1492 Capital Management LLC boosted its stake in shares of Kiromic BioPharma by 21.3% in the third quarter. 1492 Capital Management LLC now owns 434,408 shares of the company’s stock worth $1,334,000 after buying an additional 76,402 shares during the last quarter. Intellectus Partners LLC raised its holdings in Kiromic BioPharma by 32.0% in the 3rd quarter. Intellectus Partners LLC now owns 98,850 shares of the company’s stock worth $303,000 after purchasing an additional 23,950 shares during the period. LPL Financial LLC raised its holdings in Kiromic BioPharma by 59.8% in the 4th quarter. LPL Financial LLC now owns 84,400 shares of the company’s stock worth $129,000 after purchasing an additional 31,600 shares during the period. Zeke Capital Advisors LLC raised its holdings in Kiromic BioPharma by 236.7% in the 3rd quarter. Zeke Capital Advisors LLC now owns 56,899 shares of the company’s stock worth $175,000 after purchasing an additional 40,000 shares during the period. Finally, Geode Capital Management LLC acquired a new position in Kiromic BioPharma in the 3rd quarter worth about $158,000. Hedge funds and other institutional investors own 16.03% of the company’s stock.

About Kiromic BioPharma (Get Rating)

Kiromic BioPharma, Inc, a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1; and chimeric gamma delta PD1 T cell switch receptor therapy.

Further Reading

Get a free copy of the Zacks research report on Kiromic BioPharma (KRBP)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Kiromic BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiromic BioPharma and related companies with's FREE daily email newsletter.